SITC

EQS-News: BriaCell’s Lead Candidate Bria-IMT™ Shows Promising Results For Advanced Breast Cancer Patients

Retrieved on: 
Friday, December 2, 2022

BriaCells lead candidate Bria-IMT is marketed as an off-the-shelf personalized cellular approach to immunotherapy for the treatment of advanced solid tumors.

Key Points: 
  • BriaCells lead candidate Bria-IMT is marketed as an off-the-shelf personalized cellular approach to immunotherapy for the treatment of advanced solid tumors.
  • The targeted patients are advanced breast cancer patients or terminal breast cancer patients.
  • BriaCell also reports it is currently developing next-generation off-the-shelf personalized immunotherapies targeting patients with advanced breast cancer and advanced prostate cancer.
  • Bria-OTS+, for advanced breast cancer, and Bria-PROS, for advanced prostate cancer, are designed to activate nave T cells and produce a strong immune response in patients.

Site Centers Declares Fourth Quarter 2022 Class A Preferred Share Dividend

Retrieved on: 
Thursday, December 1, 2022

SITE Centers Corp. (NYSE: SITC), an owner of open-air shopping centers in suburban, high household income communities, today declared its fourth quarter 2022 Preferred Class A stock dividend of $0.39844 per depositary share.

Key Points: 
  • SITE Centers Corp. (NYSE: SITC), an owner of open-air shopping centers in suburban, high household income communities, today declared its fourth quarter 2022 Preferred Class A stock dividend of $0.39844 per depositary share.
  • Each Class A depositary share is equal to one-twentieth of a share of SITE Centers 6.375% Class A Cumulative Redeemable Preferred Stock.
  • The declared Preferred Class A dividend covers the period beginning October 15, 2022 and ending January 14, 2023.
  • The declared Preferred Class A Dividend is payable in cash on January 17, 2023 to shareholders of record at the close of business on December 30, 2022.

Oncolytics Biotech® Receives FDA Fast Track Designation for the Treatment of Advanced/Metastatic Pancreatic Cancer

Retrieved on: 
Thursday, December 1, 2022

SAN DIEGO, and CALGARY, AB, Dec. 1, 2022 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to pelareorep in combination with Roche's anti-PD-L1 checkpoint inhibitor atezolizumab, and the chemotherapeutic agents gemcitabine and nab-paclitaxel, for the treatment of advanced/metastatic pancreatic ductal adenocarcinoma (PDAC). This represents pelareorep's second FDA Fast Track designation.

Key Points: 
  • This represents pelareorep's second FDA Fast Track designation.
  • Fast Track designation is designed to facilitate the development and expedite the review of therapies to treat serious conditions and fill an unmet medical need.
  • For conditions where an available treatment exists, a therapy must show some advantage over the available treatment, such as superior effectiveness, to be granted a Fast Track designation.
  • In addition, clinical programs with Fast Track designation may be eligible for Accelerated Approval and Priority Review, if relevant criteria are met.

Oncolytics Biotech® Receives FDA Fast Track Designation for the Treatment of Advanced/Metastatic Pancreatic Cancer

Retrieved on: 
Thursday, December 1, 2022

SAN DIEGO, and CALGARY, AB, Dec. 1, 2022 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to pelareorep in combination with Roche's anti-PD-L1 checkpoint inhibitor atezolizumab, and the chemotherapeutic agents gemcitabine and nab-paclitaxel, for the treatment of advanced/metastatic pancreatic ductal adenocarcinoma (PDAC). This represents pelareorep's second FDA Fast Track designation.

Key Points: 
  • This represents pelareorep's second FDA Fast Track designation.
  • Fast Track designation is designed to facilitate the development and expedite the review of therapies to treat serious conditions and fill an unmet medical need.
  • For conditions where an available treatment exists, a therapy must show some advantage over the available treatment, such as superior effectiveness, to be granted a Fast Track designation.
  • In addition, clinical programs with Fast Track designation may be eligible for Accelerated Approval and Priority Review, if relevant criteria are met.

Oncolytics Biotech® Receives FDA Fast Track Designation for the Treatment of Advanced/Metastatic Pancreatic Cancer

Retrieved on: 
Thursday, December 1, 2022

SAN DIEGO, and CALGARY, AB, Dec. 1, 2022 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to pelareorep in combination with Roche's anti-PD-L1 checkpoint inhibitor atezolizumab, and the chemotherapeutic agents gemcitabine and nab-paclitaxel, for the treatment of advanced/metastatic pancreatic ductal adenocarcinoma (PDAC). This represents pelareorep's second FDA Fast Track designation.

Key Points: 
  • This represents pelareorep's second FDA Fast Track designation.
  • Fast Track designation is designed to facilitate the development and expedite the review of therapies to treat serious conditions and fill an unmet medical need.
  • For conditions where an available treatment exists, a therapy must show some advantage over the available treatment, such as superior effectiveness, to be granted a Fast Track designation.
  • In addition, clinical programs with Fast Track designation may be eligible for Accelerated Approval and Priority Review, if relevant criteria are met.

Oncolytics Biotech® Receives FDA Fast Track Designation for the Treatment of Advanced/Metastatic Pancreatic Cancer

Retrieved on: 
Thursday, December 1, 2022

SAN DIEGO, and CALGARY, AB, Dec. 1, 2022 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to pelareorep in combination with Roche's anti-PD-L1 checkpoint inhibitor atezolizumab, and the chemotherapeutic agents gemcitabine and nab-paclitaxel, for the treatment of advanced/metastatic pancreatic ductal adenocarcinoma (PDAC). This represents pelareorep's second FDA Fast Track designation.

Key Points: 
  • This represents pelareorep's second FDA Fast Track designation.
  • Fast Track designation is designed to facilitate the development and expedite the review of therapies to treat serious conditions and fill an unmet medical need.
  • For conditions where an available treatment exists, a therapy must show some advantage over the available treatment, such as superior effectiveness, to be granted a Fast Track designation.
  • In addition, clinical programs with Fast Track designation may be eligible for Accelerated Approval and Priority Review, if relevant criteria are met.

Oncolytics Biotech® Receives FDA Fast Track Designation for the Treatment of Advanced/Metastatic Pancreatic Cancer

Retrieved on: 
Thursday, December 1, 2022

SAN DIEGO, and CALGARY, AB, Dec. 1, 2022 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to pelareorep in combination with Roche's anti-PD-L1 checkpoint inhibitor atezolizumab, and the chemotherapeutic agents gemcitabine and nab-paclitaxel, for the treatment of advanced/metastatic pancreatic ductal adenocarcinoma (PDAC). This represents pelareorep's second FDA Fast Track designation.

Key Points: 
  • This represents pelareorep's second FDA Fast Track designation.
  • Fast Track designation is designed to facilitate the development and expedite the review of therapies to treat serious conditions and fill an unmet medical need.
  • For conditions where an available treatment exists, a therapy must show some advantage over the available treatment, such as superior effectiveness, to be granted a Fast Track designation.
  • In addition, clinical programs with Fast Track designation may be eligible for Accelerated Approval and Priority Review, if relevant criteria are met.

Memgen Reports Results From Its First-In-Human Clinical Trial of MEM-288 in Solid Tumors Refractory to Checkpoint Inhibitors at SITC 2022

Retrieved on: 
Wednesday, November 30, 2022

The interim results from this ongoing first-in-human Phase 1 trial indicate that MEM-288 is well tolerated and expands tumor-fighting T cells.

Key Points: 
  • The interim results from this ongoing first-in-human Phase 1 trial indicate that MEM-288 is well tolerated and expands tumor-fighting T cells.
  • Seven patients with solid tumors received at least one intratumoral injection of MEM-288 with no dose-limiting toxicity or discontinuation due to toxicity.
  • All 6 NSCLC patients had already received 2 to 4 lines of therapy including one or more lines with checkpoint inhibitors before enrollment.
  • Based on the early results presented at SITC, MEM-288 may successfully deploy the CD40 pathway to stimulate immune responses directed against tumors.

BioNTech and Ryvu Therapeutics Enter into Global Collaboration to Develop and Commercialize Immuno-Modulatory Small Molecule Candidates

Retrieved on: 
Wednesday, November 30, 2022

The global collaboration will consist of two parts: BioNTech will receive a global, exclusive license to develop and commercialize Ryvus STING agonist portfolio as standalone small molecules, including as monotherapy and in therapeutic combinations.

Key Points: 
  • The global collaboration will consist of two parts: BioNTech will receive a global, exclusive license to develop and commercialize Ryvus STING agonist portfolio as standalone small molecules, including as monotherapy and in therapeutic combinations.
  • BioNTech has the option to license global development and commercialization rights to these programs at the development candidate stage.
  • The collaboration with Ryvu provides us with the opportunity to complement our immunotherapy pipeline with a portfolio of potent immunomodulatory molecules.
  • BioNTech will fund all discovery, research and development activities, including Ryvus discovery and research activities under the multi-target research collaboration.

Portage Biotech Announces Results for Fiscal Quarter Ended September 30, 2022

Retrieved on: 
Tuesday, November 29, 2022

WESTPORT, Conn., Nov. 29, 2022 (GLOBE NEWSWIRE) -- Portage Biotech Inc., (NASDAQ: PRTG) (“Portage” or the “Company”), a clinical-stage immuno-oncology company developing therapies to improve patient lives and increase survival by avoiding and overcoming cancer treatment resistance, today announced financial results for the fiscal quarter ended September 30, 2022.

Key Points: 
  • WESTPORT, Conn., Nov. 29, 2022 (GLOBE NEWSWIRE) -- Portage Biotech Inc., (NASDAQ: PRTG) (Portage or the Company), a clinical-stage immuno-oncology company developing therapies to improve patient lives and increase survival by avoiding and overcoming cancer treatment resistance, today announced financial results for the fiscal quarter ended September 30, 2022.
  • Research & development costs increased by approximately $0.2 million, or approximately 15%, from approximately $1.3 million in the Fiscal 2022 Quarter, to approximately $1.5 million in the Fiscal 2023 Quarter.
  • Additionally, the Company incurred payroll-related expenses of $0.5 million in Fiscal 2023 Quarter, compared to $0.2 million in the Fiscal 2022 Quarter.
  • General and administrative expenses increased by approximately $0.1 million, or approximately 5%, from approximately $2.0 million in the Fiscal 2022 Quarter, to approximately $2.1 million in the Fiscal 2023 Quarter.